OCUGEN INC. - COMMON STOCK

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

09 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

16 дек 2022 06:30:56 Источник Nasdaq GlobeNewswire

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

15 дек 2022 17:15:49 Источник Nasdaq GlobeNewswire

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

13 дек 2022 08:00:02 Источник Nasdaq GlobeNewswire

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

07 дек 2022 08:00:01 Источник Nasdaq GlobeNewswire

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

28 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

08 ноя 2022 07:30:34 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

27 окт 2022 07:30:25 Источник Nasdaq GlobeNewswire

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

19 окт 2022 07:30:00 Источник Nasdaq GlobeNewswire

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

12 окт 2022 17:37:42 Источник Nasdaq GlobeNewswire

Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

06 окт 2022 08:00:28 Источник Nasdaq GlobeNewswire

Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

29 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

28 сен 2022 06:30:22 Источник Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 сен 2022 17:07:00 Источник Nasdaq GlobeNewswire

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

14 сен 2022 06:30:26 Источник Nasdaq GlobeNewswire

Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference

08 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference

06 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

01 сен 2022 07:30:16 Источник Nasdaq GlobeNewswire

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

12 авг 2022 07:30:22 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update & Second Quarter 2022 Financial Results

05 авг 2022 07:30:26 Источник Nasdaq GlobeNewswire